Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca In Buy Now, Pay In Full Later Deal For Majority Acerta Stake

This article was originally published in Scrip

Executive Summary

In a move which AstraZeneca PLC says "completes its transformation in oncology," it is acquiring a 55% stake in privately held Dutch biotech Acerta Pharma BV for $4bn, made up of $2.5bn now and $1.5bn later. The deal also includes an option to acquire the remainder of the company for a further $3bn.

You may also be interested in...



Finance Watch: Biopharma VC Deals Hit New Record Of $27.4bn In 2020

Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.

Finance Watch: BioGeneration Ventures, Autobahn Labs Offer New Start-Up Resources

Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.

Positive CLL Data For AstraZeneca's BTK Inhibitor Prompts Early ASCEND Trial End

The Calquence Phase III ASCEND trial met its primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukemia and thus will stop early.

Related Content

Topics

UsernamePublicRestriction

Register

SC064017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel